Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Shojaei, Farbod ^a   Scott, Nathan ^b   Kang, Xiaolin ^a   Lappin, Patrick B ^a   Fitzgerald, Amanda A ^b   Karlicek, Shannon ^a   Simmons, Brett H ^a   Wu, Aidong ^a   Lee, Joseph H ^a   Bergqvist, Simon ^a   Kraynov, Eugenia ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI OSTEOPONTIN MONOCLONAL ANTIBODY 1; ARGINYLGLYCYLASPARTIC ACID; CARBOPLATIN; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; INTEGRIN; MONOCLONAL ANTIBODY; OSTEOPONTIN; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; THROMBIN; UNCLASSIFIED DRUG; CHEMOTACTIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DISEASE COURSE; DRUG BINDING SITE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN CELL; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS; METASTASIS INHIBITION; MONOCYTE; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE PLASMON RESONANCE; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DISEASE MODEL; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MOLECULAR GENETICS; MOUSE MUTANT; PROTEIN BINDING; PROTEIN STABILITY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTACTIC FACTORS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTEGRINS; LUNG NEOPLASMS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; OSTEOPONTIN; PROTEIN BINDING; PROTEIN STABILITY; THROMBIN;

EID: 84862784596     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-26     Document Type: Article

References (55)

1. Osteopontin: an effector and an effect of tumor metastasis. Shevde LA, Das S, Clark DW, Samant RS, Curr Mol Med 2010 10 71 81 10.2174/ 156652410791065381 20205680
2. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS, Biochem Biophys Res Commun 2001 280 460 465 10.1006/bbrc.2000.4146 11162539 (Pubitemid 32912812)
3. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Weber GF, Ashkar S, Glimcher MJ, Cantor H, Science 1996 271 509 512 10.1126/science.271.5248.509 8560266 (Pubitemid 26044470)
4. Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. McKee MD, Nanci A, Connect Tissue Res 1996 35 197 205 10.3109/03008209609029192 9084658 (Pubitemid 27118851)
5. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Hui EP, Sung FL, Yu BK, Wong CS, Ma BB, Lin X, Chan A, Wong WL, Chan AT, Clin Cancer Res 2008 14 7080 7087 10.1158/1078-0432.CCR-08- 0364 18981006
6. Identification of osteopontin (OPN) mRNA and protein in the rat testis and epididymis, and on sperm. Siiteri JE, Ensrud KM, Moore A, Hamilton DW, Mol Reprod Dev 1995 40 16 28 10.1002/mrd.1080400104 7702867
7. Caprine uterine and placental osteopontin expression is distinct among epitheliochorial implanting species. Joyce MM, Gonzalez JF, Lewis S, Woldesenbet S, Burghardt RC, Newton GR, Johnson GA, Placenta 2005 26 160 170 10.1016/j.placenta.2004.05.009 15708117 (Pubitemid 40247004)
8. Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Tuck AB, Hota C, Chambers AF, Breast Cancer Res Treat 2001 70 197 204 10.1023/A:1013095329825 11804183 (Pubitemid 34015515)
9. Osteopontin expression and regulation in the testis, efferent ducts, and epididymis of rats during postnatal development through to adulthood. Luedtke CC, McKee MD, Cyr DG, Gregory M, Kaartinen MT, Mui J, Hermo L, Biol Reprod 2002 66 1437 1448 10.1095/biolreprod66.5.1437 11967208 (Pubitemid 34462288)
10. Isoform-specific O-glycosylation of osteopontin and bone sialoprotein by polypeptide N-acetylgalactosaminyltransferase-1. Miwa HE, Gerken TA, Jamison O, Tabak LA, J Biol Chem 2010 285 1208 1219 10.1074/jbc.M109.035436 19880513
11. Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Shanmugam V, Chackalaparampil I, Kundu GC, Mukherjee AB, Mukherjee BB, Biochemistry 1997 36 5729 5738 10.1021/bi961687w 9153413 (Pubitemid 27214924)
12. Osteopontin-c is a selective marker of breast cancer. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF, Int J Cancer 2008 122 889 897 10.1002/ijc.23204 17960616
13. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ, J Natl Cancer Inst 2002 94 513 521 10.1093/jnci/94.7.513 11929952 (Pubitemid 34411290)
14. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ, Clin Cancer Res 2004 10 184 190 10.1158/1078-0432.CCR-1405-2 14734468 (Pubitemid 38114178)
15. Osteopontin expression in lung cancer. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG, Lung Cancer 1996 15 311 323 10.1016/0169-5002(95)00595-1 8959677 (Pubitemid 26399511)
16. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF, Cancer 2002 95 506 512 10.1002/cncr.10709 12209742 (Pubitemid 34810175)
17. Osteopontin: possible role in prostate cancer progression. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW, Clin Cancer Res 1999 5 2271 2277 10473115 (Pubitemid 29399287)
18. Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM, Circ Res 1995 77 665 672 7554111
19. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. Philip S, Bulbule A, Kundu GC, J Biol Chem 2001 276 44926 44935 10.1074/jbc.M103334200 11564733
20. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF, Oncogene 1999 18 4237 4246 10.1038/sj.onc.1202799 10435636 (Pubitemid 29377854)
21. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM, J Clin Invest 1995 95 713 724 10.1172/JCI117718 7532190
22. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF, Mol Carcinog 2005 43 225 236 10.1002/mc.20105 15864800 (Pubitemid 41134430)
23. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G, Breast Cancer Res Treat 2000 59 271 278 10.1023/A:1006308619659 10832597 (Pubitemid 30243049)
24. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM, J Cell Biol 1998 141 1083 1093 10.1083/jcb.141.4.1083 9585425 (Pubitemid 28243974)
25. Osteopontin deficiency in rat vascular smooth muscle cells is associated with an inability to adhere to collagen and increased apoptosis. Weintraub AS, Schnapp LM, Lin X, Taubman MB, Lab Invest 2000 80 1603 1615 10.1038/labinvest. 3780171 11092521
26. Tumor angiogenesis: therapeutic implications. Folkman J, N Engl J Med 1971 285 1182 1186 10.1056/NEJM197111182852108 4938153
27. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T, Br J Cancer 2000 82 1967 1973 10864205 (Pubitemid 30326458)
28. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Chakraborty G, Jain S, Kundu GC, Cancer Res 2008 68 152 161 10.1158/0008-5472. CAN-07-2126 18172307 (Pubitemid 351380116)
29. Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. Guo H, Cai CQ, Schroeder RA, Kuo PC, J Immunol 2001 166 1079 1086 11145688 (Pubitemid 32060266)
30. Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Attur MG, Dave MN, Stuchin S, Kowalski AJ, Steiner G, Abramson SB, Denhardt DT, Amin AR, Arthritis Rheum 2001 44 578 584 10.1002/1529-0131(200103)44:3<578::AID- ANR106>3.0.CO;2-7 11263772 (Pubitemid 32234616)
31. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. Beausoleil MS, Schulze EB, Goodale D, Postenka CO, Allan AL, BMC Cancer 2011 11 25 10.1186/1471-2407-11-25 21247495
32. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Senger DR, Perruzzi CA, Biochim Biophys Acta 1996 1314 13 24 10.1016/S0167-4889(96)00067-5 8972713 (Pubitemid 26395494)
33. Thrombin-cleaved COOH(-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Mi Z, Oliver T, Guo H, Gao C, Kuo PC, Cancer Res 2007 67 4088 4097 10.1158/0008-5472.CAN-06-4066 17483319 (Pubitemid 46815053)
34. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos Sergiou A, Peruzzi CA, Detmar M, Am-J-Pathol 1996 149 293 305 issn: 0002-9440 8686754 (Pubitemid 26231000)
35. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG, Cancer Res 2010 70 10090 10100 10.1158/0008-5472.CAN-10-0489 20952508
36. Pre- and post-translational regulation of osteopontin in cancer. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF, J Cell Commun Signal 2011 5 111 122 10.1007/s12079-011-0130-6 21516514
37. Osteopontin as a target for cancer therapy. Johnston NI, Gunasekharan VK, Ravindranath A, O'Connell C, Johnston PG, El-Tanani MK, Front Biosci 2008 13 4361 4372 18508515 (Pubitemid 351599688)
38. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, Furuse K, Mack PC, J Thorac Oncol 2009 4 1104 1110 10.1097/JTO.0b013e3181ae2844 19620934
39. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS, J Clin Oncol 2010 28 936 941 10.1200/JCO.2009.25.5711 20085934
40. Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry. Wu J, Pungaliya P, Kraynov E, Bates B, Biomarkers 2012
41. How genetically engineered mouse tumor models provide insights into human cancers. Politi K, Pao W, J Clin Oncol 2011 29 2273 2281 10.1200/JCO.2010.30. 8304 21263096
42. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. DuPage M, Dooley AL, Jacks T, Nat Protoc 2009 4 1064 1072 10.1038/nprot.2009.95 19561589
43. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, Hrabe de Angelis M, Schlederer M, Mair M, Kenner L, Plutzky J, Zeyda M, Stulnig TM, Diab tologia 2011 54 2132 2142
44. Altered wound healing in mice lacking a functional osteopontin gene (spp 1). Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL, J Clin Invest 1998 101 1468 1478 9525990 (Pubitemid 28166845)
45. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Crawford HC, Matrisian LM, Liaw L, Cancer Res 1998 58 5206 5215 9823334 (Pubitemid 28521184)
46. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, Tsuji K, Nifuji A, Denhardt DT, Noda M, J Bone Miner Res 2001 16 652 659 10.1359/jbmr.2001.16.4.652 11315992 (Pubitemid 32230593)
47. Down-regulation of osteopontin attenuates breast tumour progression in vivo. Chakraborty G, Jain S, Patil TV, Kundu GC, J Cell Mol Med 2008 12 2305 2318 10.1111/j.1582-4934.2008.00263.x 18266970
48. Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, Jin Y, Li W, J Cancer Res Clin Oncol 2011 137 1061 1070 10.1007/s00432-010-0968-7 21207061
49. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS, J Thorac Oncol 2010 5 1516 1523 10.1097/JTO.0b013e3181eba6bd 20689445
50. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Lung Cancer 2007 57 373 380 10.1016/j.lungcan.2007.04.005 17513004 (Pubitemid 47285428)
51. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. Blasberg JD, Goparaju CM, Pass HI, Donington JS, J Thorac Cardiovasc Surg 2010 139 1587 1593 10.1016/j.jtcvs.2009.08.016 19818970
52. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR, J Clin Oncol 2008 26 4771 4776 10.1200/JCO.2008.17.0662 18779603
53. Mouse models for human lung cancer. Meuwissen R, Berns A, Genes Dev 2005 19 643 664 10.1101/gad.1284505 15769940 (Pubitemid 40395076)
54. The Catalogue of Somatic Mutations in Cancer (COSMIC). Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR, Curr Protoc Hum Genet 2008 Chapter 10 Unit 10 11
55. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T, Shepherd FA, J Clin Oncol 2007 25 5240 5247 10.1200/JCO.2007.12.6953 18024870 (Pubitemid 350232256)